دراسة عن لازيرتينيب مع أميڤانتاماب تحت الجلد مقارنة بأميڤانتاماب عن طريق الوريد في المشاركين المصابين بسرطان الرئة غير صغير الخلايا المتقدم أو النقيلي مع طفرة في مستقبل عامل النمو البشري (EGFR)
This study is looking at people with a type of advanced lung cancer called non-small cell lung cancer, which has specific genetic changes (EGFR mutations). We are comparing two ways to give a medicine called amivantamab. One way is the standard intravenous (into a vein) drip. The other is a new version of amivantamab given as an injection under the skin. The main goal is to see if this new injection is simpler and quicker to give, making it a better experience for patients and medical staff. We want to understand if it works just as well and is safe.
نظرة سريعة
النتائج
نتائج هذه الدراسة
تم النشر فبراير 2026تم نشر نتائج هذه الدراسة.
ما هو موضوع هذه الدراسة؟
This research study is about a type of advanced lung cancer called non-small cell lung cancer. Specifically, it's for people whose cancer has certain genetic changes, known as EGFR mutations. We're interested in improving how a vital medicine called amivantamab is given.
Currently, amivantamab is usually given to patients through a drip into a vein. This can take a while and sometimes isn't the most convenient for patients or doctors. The aim of this study is to test a new version of the medicine that can be given as an injection just under the skin. This new injection is designed to be much simpler and quicker to administer.
By comparing the injection with the current drip method, we want to find out if the new injection works just as well, is safe, and makes the treatment experience better for patients. We hope it can offer a more comfortable and efficient way for people to receive their treatment.
النقاط الرئيسية
- This study compares two ways to give advanced lung cancer medicine: drip vs. injection.
- It's for people with a specific type of EGFR-mutated non-small cell lung cancer.
- The goal is to find a simpler, quicker, and patient-friendly way to give treatment.
- Participation includes regular clinic visits, blood tests, and scans.
- You will receive either the drip or the experimental injection plus lazertinib.
من قد يكون مؤهلاً؟
To join this study, you need to have a specific type of advanced non-small cell lung cancer that has certain genetic changes (called EGFR Exon 19 deletion or Exon 21 L858R mutation). Your cancer must have gotten worse after you've already had certain treatments, including osimertinib (or a similar medicine) and platinum-based chemotherapy.
You also need to be generally well enough to take part, meaning you can mostly look after yourself. The medical team will check if there's at least one part of your cancer that can be measured to see how well the treatment is working. Any side effects from previous treatments must have mostly cleared up.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Do you have advanced non-small cell lung cancer with specific EGFR mutations?
- Has your cancer progressed after treatments like osimertinib and chemotherapy?
- Are you generally well and able to mostly look after yourself (ECOG 0-1)?
- Have your previous treatment side effects mostly cleared up?
- Is there at least one area of your cancer that can be measured by scans?
ماذا يتضمن المشاركة؟
If you join this study, you will either receive the standard amivantamab medicine through a drip into your vein OR the new amivantamab injection under your skin, along with another medicine called lazertinib. You won't get to choose which group you are in; it will be decided randomly.
Throughout the study, you'll have regular hospital visits for your treatment, blood tests, scans (like CT scans) to check your progress, and health checks by doctors and nurses. These appointments will help the research team see how the treatment is working and if you have any side effects. The total length of your participation will depend on how you respond to the treatment and what the study doctors advise.
المخاطر والفوائد المحتملة
المواقع (187)
- City of Hope Duarteالرمز البريدي المؤكددوارتي، الولايات المتحدة
- مركز مدينة الأمل لمؤسسة لينار لمكافحة السرطان في مقاطعة أورانجالرمز البريدي المؤكدإرفاين، الولايات المتحدة
- City of Hope Long Beach Elmالرمز البريدي المؤكدلونغ بيتش، الولايات المتحدة
- الصحة اليهودية الوطنيةالرمز البريدي المؤكددنفر، الولايات المتحدة
- Baptist Lynn Cancer Instituteالرمز البريدي المؤكدبوكا راتون، الولايات المتحدة
- Orlando Healthالرمز البريدي المؤكدأورلاندو، الولايات المتحدة
- جامعة كانساسالرمز البريدي المؤكدكانساس سيتي، الولايات المتحدة
- University of Michiganالرمز البريدي المؤكدآن آربر، الولايات المتحدة
- Astera Cancer Careالرمز البريدي المؤكدEast Brunswick, United States
- معهد روتجرز للسرطان في نيو جيرسيالرمز البريدي المؤكدنيو برونزويك، الولايات المتحدة
- NYU Langone Health Laura and Isaac Perlmutter Cancer Centerالرمز البريدي المؤكدنيويورك، الولايات المتحدة
- مركز مونتيفيوري الطبيالرمز البريدي المؤكدذا برونكس، الولايات المتحدة
أسئلة شائعة
What is EGFR-mutated lung cancer?
It's a type of lung cancer where the cancer cells have specific changes in a gene called EGFR, which can sometimes make the cancer grow.
What is amivantamab?
It's a medicine used to treat this type of lung cancer, designed to block the signals that make cancer cells grow.
What does 'subcutaneous' mean?
It means the medicine is given as an injection just under your skin, rather than directly into a vein.
What is 'lazertinib'?
Lazertinib is another medicine that researchers are studying alongside amivantamab for this type of lung cancer.
كم ستستغرق مدة الدراسة؟
The length of your participation will depend on your individual response to the treatment and your doctor's advice.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.